Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for Prevention of Contrast Induced Nephropathy in CKD Patients in ICU
NCT07561801Completed
- Sponsor
- Tanta University
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of pentoxifylline in contrast-induced nephropathy (CIN) (2 arms), sponsored by Tanta University. Primary endpoint: Incidence of contrast induced nephropathy at 48 hours. Started Jul 2024; status: completed.
02
Drugs
pentoxifylline
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT07561801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561801.